• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Organogenesis Holdings Inc.

    8/14/25 4:33:14 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORGO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Organogenesis Holdings, Inc.

    (Name of Issuer)


    Common Stock, $0.01 par value

    (Title of Class of Securities)


    68621F102

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68621F102


    1Names of Reporting Persons

    First Light Asset Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,061,404.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,061,404.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,061,404.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.35 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    68621F102


    1Names of Reporting Persons

    Mathew P. Arens
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    231,000.00
    6Shared Voting Power

    8,078,404.00
    7Sole Dispositive Power

    231,000.00
    8Shared Dispositive Power

    8,078,404.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,309,404.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.55 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Organogenesis Holdings, Inc.
    (b)Address of issuer's principal executive offices:

    85 Dan Road, Canton, MA 02021
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is jointly filed by the following: First Light Asset Management, LLC (the "Manager") Mathew P. Arens ("Mr. Arens") The Manager may be deemed to be the beneficial owner of 8,061,404 of the Issuer's shares of common stock (the "Shares"). The Manager acts as an investment adviser to certain persons holding separately managed accounts with the Manager, each of whom has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of,those shares. The Manager may also be deemed to be the beneficial owner of these shares because it acts as an investment adviser to certain private funds. Mr. Arens may also be deemed to be the beneficial owner of these shares because he controls the Manager in his position as managing member and majority owner of the Manager. Mr. Arens also directly holds 231,000 Shares in an individual capacity with sole control and 17,000 Shares held in a joint account over which he shares control. The Manager and Mr. Arens are filing this Schedule 13G/A with respect to these Shares pursuant to Rule 13d-1(b) under the Act. The Manager and Mr. Arens may be deemed to be the beneficial owner of the total amount of Shares set forth across from its or his respective name in Item 4 below. The filing of this Schedule 13G shall not be construed as an admission that the reporting persons or any of their affiliates are the beneficial owner of any securities covered by this Schedule 13G for any other purposes other than Section 13(d) of the Securities Exchange Act of 1934.
    (b)Address or principal business office or, if none, residence:

    Each of the reporting persons identified in Item 2(a) has its principal business office at: 3300 Edinborough Way, Suite 201, Edina, MN 55435
    (c)Citizenship:

    First Light Asset Management, LLC - Delaware limited liability company Mathew P. Arens - United States citizen
    (d)Title of class of securities:

    Common Stock, $0.01 par value
    (e)CUSIP No.:

    68621F102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    First Light Asset Management, LLC - 8,061,404 Mathew P. Arens - 8,309,404
    (b)Percent of class:

    First Light Asset Management, LLC - 6.35% Mathew P. Arens - 6.55%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    First Light Asset Management, LLC - 0 Mathew P. Arens - 231,000

     (ii) Shared power to vote or to direct the vote:

    First Light Asset Management, LLC - 8,061,404 Mathew P. Arens - 8,078,404

     (iii) Sole power to dispose or to direct the disposition of:

    First Light Asset Management, LLC - 0 Mathew P. Arens - 231,000

     (iv) Shared power to dispose or to direct the disposition of:

    First Light Asset Management, LLC - 8,061,404 Mathew P. Arens - 8,078,404

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    First Light Asset Management, LLC
     
    Signature:/s/ Kurt T. Peterson
    Name/Title:Kurt T. Peterson/Chief Compliance Officer
    Date:08/14/2025
     
    Mathew P. Arens
     
    Signature:/s/ Mathew P. Arens
    Name/Title:Mathew P. Arens/Chief Executive Officer
    Date:08/14/2025
    Exhibit Information

    Exhibit A: Joint Filing Agreement

    Get the next $ORGO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORGO

    DatePrice TargetRatingAnalyst
    6/28/2024$5.00Buy
    Lake Street
    2/7/2024$5.00Overweight
    Cantor Fitzgerald
    6/15/2023$5.00Equal-Weight
    Morgan Stanley
    5/24/2023$10.00Neutral → Buy
    BTIG Research
    11/10/2022Buy → Neutral
    BTIG Research
    8/10/2022Outperform → Perform
    Oppenheimer
    11/10/2021$26.00 → $20.00Outperform
    SVB Leerink
    8/10/2021$24.00 → $25.00Outperform
    Credit Suisse
    More analyst ratings

    $ORGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

    CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared to net product revenue of $130.2 million for the second quarter of 2024. Net product revenue for the second quarter of 2025 consists of: Net product revenue from Advanced Wound

    8/7/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

    CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Eastern Time on August 7th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the

    7/22/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation

    CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds the Centers for Medicare & Medicaid Services' (CMS) proposed new payment approach for skin substitutes/cellular and tissue-based products (CTPs) under the CY 2026 Physician Fee Schedule and urges CMS to establish 2026 payment rates based on clinical value and relative cost. "We are pleased CMS is proposing a per centimeter square payment methodology based on FDA classification for skin substitutes i

    7/15/25 9:00:00 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Grow Brian exercised 4,060 shares at a strike of $2.47 and covered exercise/tax liability with 2,173 shares, increasing direct ownership by 0.28% to 672,377 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    8/13/25 4:08:38 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vice President, Strategy Cavorsi Robert covered exercise/tax liability with 360 shares, decreasing direct ownership by 0.19% to 189,165 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    7/18/25 4:13:38 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Admin. and Legal Officer Freedman Lori bought $725,290 worth of shares (252,264 units at $2.88), increasing direct ownership by 42% to 846,459 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    6/6/25 5:44:18 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Organogenesis Holdings Inc.

    SCHEDULE 13G - Organogenesis Holdings Inc. (0001661181) (Subject)

    8/14/25 4:33:14 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Organogenesis Holdings Inc.

    S-8 - Organogenesis Holdings Inc. (0001661181) (Filer)

    8/7/25 4:27:20 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Organogenesis Holdings Inc.

    10-Q - Organogenesis Holdings Inc. (0001661181) (Filer)

    8/7/25 4:16:48 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Organogenesis with a new price target

    Lake Street initiated coverage of Organogenesis with a rating of Buy and set a new price target of $5.00

    6/28/24 8:20:16 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Organogenesis with a new price target

    Cantor Fitzgerald initiated coverage of Organogenesis with a rating of Overweight and set a new price target of $5.00

    2/7/24 6:56:39 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Organogenesis with a new price target

    Morgan Stanley initiated coverage of Organogenesis with a rating of Equal-Weight and set a new price target of $5.00

    6/15/23 7:30:00 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Admin. and Legal Officer Freedman Lori bought $725,290 worth of shares (252,264 units at $2.88), increasing direct ownership by 42% to 846,459 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    6/6/25 5:44:18 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Financials

    Live finance-specific insights

    View All

    Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

    CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared to net product revenue of $130.2 million for the second quarter of 2024. Net product revenue for the second quarter of 2025 consists of: Net product revenue from Advanced Wound

    8/7/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

    CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Eastern Time on August 7th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the

    7/22/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

    CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to net revenue of $110.0 million for the first quarter of 2024. Net revenue for the first quarter of 2025 consists of: Net revenue from Advanced Wound Care products of $79.9 mill

    5/8/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Leadership Updates

    Live Leadership Updates

    View All

    Organogenesis Expands Manufacturing Capacity to Support Future Growth

    CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. "We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth," said Gary S. Gillheeney, Sr., President, Chief Executive Officer, a

    11/22/24 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

    CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that it has entered into a Subscription Agreement with affiliates of Avista Healthcare Partners ("Investors") for the sale of its Series A Convertible Preferred Stock ("Preferred Stock") in a private placement for gross proceeds of $130 million to the Company, prior to deducting placement agent commissions, fees and other offering expenses. The Company intends to use the net proceeds from the

    11/12/24 4:01:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

    Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive me

    7/3/23 6:00:00 AM ET
    $BNOX
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Organogenesis Holdings Inc.

    SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/19/24 4:05:57 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Organogenesis Holdings Inc.

    SC 13D/A - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/14/24 8:09:56 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Organogenesis Holdings Inc.

    SC 13G/A - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/14/24 3:35:42 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care